Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
Journal of Clinical Oncology · 01.03.2023 · 41 (7) · 1470-1491
DOI: 10.1200/jco.22.02331 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.03.2023. Verfasst von Manish A Shah und 26 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medicine, New York, NY. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Stomach Neoplasms. Die Arbeit wurde bisher 214-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Abstract (Originalsprache)
PURPOSE To develop recommendations involving targeted therapies for patients with advanced gastroesophageal cancer. METHODS The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS Eighteen randomized controlled trials met the inclusion criteria for the systematic review. RECOMMENDATIONS For human epidermal growth factor receptor 2 (HER2)–negative patients with gastric adenocarcinoma (AC) and programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥ 5, first-line therapy with nivolumab and chemotherapy (CT) is recommended. For HER2-negative patients with esophageal or gastroesophageal junction (GEJ) AC and PD-L1 CPS ≥ 5, first-line therapy with nivolumab and CT is recommended. First-line therapy with pembrolizumab and CT is recommended for HER2-negative patients with esophageal or GEJ AC and PD-L1 CPS ≥ 10. For patients with esophageal squamous cell carcinoma and PD-L1 tumor proportion score ≥ 1%, nivolumab plus CT, or nivolumab plus ipilimumab is recommended; for patients with esophageal squamous cell carcinoma and PD-L1 CPS ≥ 10, pembrolizumab plus CT is recommended. For patients with HER2-positive gastric or GEJ previously untreated, unresectable or metastatic AC, trastuzumab plus pembrolizumab is recommended, in combination with CT. For patients with advanced gastroesophageal or GEJ AC whose disease has progressed after first-line therapy, ramucirumab plus paclitaxel is recommended. For HER2-positive patients with gastric or GEJ AC who have progressed after first-line therapy, trastuzumab deruxtecan is recommended. In all cases, participation in a clinical trial is recommended as it is the panel's expectation that targeted treatment options for gastroesophageal cancer will continue to evolve. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Weill Cornell Medicine, New York, NY.
- American Society of Clinical Oncology, Alexandria, VA.
- Clinica Santa Beatriz, Lima, Peru.
- McGill University Health Center Research Institute, Montreal, Canada.
- St Joseph Mercy Hospital, Ann Arbor, MI.
- DeGregorio Family Foundation, Pleasantville, NY.
ORCID-Profile: Manish A Shah, Erin B Kennedy, Ashley E Alarcon-Rozas, Thierry Alcindor, Dana C Deighton, Yelena Janjigian, Asha Karippot, Uqba Khan, Daniel A King, Kelsey Klute, Rutika Mehta, Arun Nagarajan, Haeseong Park, Anwaar Saeed, Kohei Shitara, Zev Wainberg
Zitieren
APA
Shah, M. A., Kennedy, E. B., Alarcon-Rozas, A. E., Alcindor, T., Bartley, A. N., Malowany, A. B., Bhadkamkar, N. A., Deighton, D. C., Janjigian, Y., Karippot, A., Khan, U., King, D. A., Klute, K., Lacy, J., Lee, J. J., Mehta, R., Mukherjee, S., Nagarajan, A., Park, H., …, & Rajdev, L. (2023). Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. Journal of Clinical Oncology, 41(7), 1470-1491. https://doi.org/10.1200/jco.22.02331
Vancouver
Shah MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, Bartley AN, Malowany AB, et al. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. Journal of Clinical Oncology. 2023;41(7):1470-1491. doi:10.1200/jco.22.02331
BibTeX
@article{Shah2023,
author = {Shah, Manish A and Kennedy, Erin B and Alarcon-Rozas, Ashley E and Alcindor, Thierry and Bartley, Angela N and Malowany, Aubrey Belk and Bhadkamkar, Nishin A and Deighton, Dana C and Janjigian, Yelena and Karippot, Asha and Khan, Uqba and King, Daniel A and Klute, Kelsey and Lacy, Jill and Lee, James J and Mehta, Rutika and Mukherjee, Sarbajit and Nagarajan, Arun and Park, Haeseong and Saeed, Anwaar and Semrad, Thomas J and Shitara, Kohei and Smyth, Elizabeth and Uboha, Natalia V and Vincelli, Melani and Wainberg, Zev and Rajdev, Lakshmi},
title = {Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {7},
pages = {1470--1491},
doi = {10.1200/jco.22.02331}
}
EUVIMED